Clinical trials
Phase 3 Colonic Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
81 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 6 |
| 2001 | 4 |
| 2003 | 4 |
| 2004 | 5 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 6 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Terminated | 17 |
| Recruiting | 5 |
| Active, not recruiting | 5 |
| Unknown status | 5 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 13 |
| Alliance for Clinical Trials in Oncology | 12 |
| NSABP Foundation Inc | 5 |
| Pfizer | 3 |
| Amgen | 2 |
| Braintree Laboratories | 2 |
| Massachusetts General Hospital | 2 |
| Novartis | 2 |
| SWOG Cancer Research Network | 2 |
| Sanofi | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colonic Neoplasms | 81 |
| Rectal Neoplasms | 49 |
| Colorectal Neoplasms | 48 |
| Neoplasm Metastasis | 8 |
| Breast Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Lung Neoplasms | 4 |
| Neoplasms | 4 |
| Prostatic Neoplasms | 4 |
| Adenomatous Polyps | 3 |
Trials
Showing 1 to 25 of 81. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.